secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001104659-24-047974
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm CEO Steps Down, CMO Promoted; Phase 3b Trial for NurOwn Planned
--------------------------------------------------------------------------

- Co-CEO Stacy Lindborg resigns effective May 9, 2024, but will join the Board of Directors.
- Dr. Bob Dagher promoted from Chief Development Officer to Executive VP and Chief Medical Officer.
- Company plans registrational Phase 3b trial for NurOwn (ALS) under FDA Special Protocol Assessment.
- Separation agreement includes $300,000 lump sum payment and continued vesting of certain equity awards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924047974/0001104659-24-047974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924047974/tm2412023d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-047974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer